Kymera Therapeutics’ (KYMR) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research report report published on Thursday,Benzinga reports. BTIG Research currently has a $138.00 price target on the stock.

Other analysts have also issued research reports about the stock. Truist Financial increased their price objective on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Morgan Stanley increased their price target on Kymera Therapeutics from $73.00 to $127.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Stifel Nicolaus set a $114.00 price objective on Kymera Therapeutics in a report on Monday, December 8th. Finally, Guggenheim started coverage on Kymera Therapeutics in a report on Monday, November 3rd. They set a “buy” rating and a $90.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of “Buy” and a consensus price target of $116.30.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $69.54 on Thursday. Kymera Therapeutics has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The firm has a market capitalization of $5.00 billion, a PE ratio of -19.37 and a beta of 2.21. The stock’s 50-day simple moving average is $74.20 and its 200-day simple moving average is $57.96.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The firm had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $23.15 million. Sell-side analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Activity

In related news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were bought at an average cost of $86.00 per share, with a total value of $172,499,918.00. Following the purchase, the director directly owned 7,955,916 shares of the company’s stock, valued at approximately $684,208,776. This represents a 33.71% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have sold 450,895 shares of company stock worth $39,608,051. Insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently made changes to their positions in the company. US Bancorp DE raised its stake in Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Kymera Therapeutics by 9.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after buying an additional 248 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after acquiring an additional 540 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.